Cargando…
Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
Biosimilars are biologic products that are highly similar, but not identical, to a licensed reference (or "originator") biologic product. These agents have the potential to provide efficiencies and improve access to treatment for patients. Biosimilars are currently available for use in cli...
Autores principales: | Tinsley, Sara M., Grande, Carolyn, Olson, Karin, Plato, Leah, Jacobs, Ira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570521/ https://www.ncbi.nlm.nih.gov/pubmed/31249718 |
Ejemplares similares
-
Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015) -
Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015) -
Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015) -
Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018) -
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)